A path to fair drug pricing: examining competition, value, & access (highlights) | Kaiser Permanente

Kaiser Permanente Institute for Health Policy Forum
A path to fair drug pricing: examining competition, value, and access
July 15, 2025

During the Kaiser Permanente Institute for Health Policy forum, experts discussed emerging solutions to address policies and tactics that currently enable high drug prices.

For full event details please visit: https://www.kpihp.org/ihp_events/a-pa...

Speakers:

Tahir Amin, LL.B., Dip. LP.
CEO, Initiative for Medicines, Access & Knowledge
I-MAK

Lauren Aronson
Executive Director, The Campaign for Sustainable Drug Pricing (CSRxP); Partner
Mehlman Consulting

Jerry Avorn, MD
Professor of Medicine
Chief Emeritus, Division of Pharmacoepidemiology and Pharmacoeconomics; Co-Director, Program on Regulation, Therapeutics, and Law
Harvard Medical School

Anthony Barrueta, JD
Senior Vice President, Government Relations
Kaiser Permanente

Adriane Fugh-Berman, MD
Director
PharmedOut
Professor
Georgetown University

Dan Gorenstein
Executive Editor
Tradeoffs Podcast

Krysten Joyce, MPH
Senior Policy Consultant
Kaiser Permanente Institute for Health Policy

Anna Kaltenboeck, MA, MBA
President
Verdant Research

Kim Le, PharmD
Interim Senior Vice President & Chief Pharmacy Officer, National Pharmacy Services
Kaiser Permanente

Kristi Martin, MA, MPA
President
Highway 136 Consulting
Director
Camber Collective

Cecilia Oregón, MPP, MPH
Executive Director
Kaiser Permanente Institute for Health Policy

Leigh Purvis, MPA
Prescription Drug Policy Principal
AARP Public Policy Institute

Conor Sheehey, MAT
Director
Leavitt Partners
Former Senior Health Counsel
U.S. Senate Committee on Finance

Polly Webster, JD, MPH
Senior Health Counsel
U.S. Senate Committee on Finance

Marta Wosińska, PhD
Senior Fellow
Center on Health Policy
The Brookings Institution